Eung Bae Lee

Eung Bae Lee

Auto-generated profile, based on publicly available information

Eung Bae Lee

Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2010 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
SCSukki Cho
Sukki Cho
YDYoung Woo Do
Young Woo Do
ELEung Bae Lee
Eung Bae Lee

1 August 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
SCSukki Cho
Sukki Cho
KRKyung-Min Ryu
Kyung-Min Ryu
YHYoon-Jin Hwang
Yoon-Jin Hwang
ELEung Bae Lee
Eung Bae Lee
Hepatocellular carcinoma (HCC) is prevalent in Asia and is the third leading cause of cancer death in Korea.1 x 1 Korea National Statistical Office. Annual Report on the Cause of Death Statistics of 2005, Seoul, 2006. Google Scholar See all References With recent advances in diagnosis and treatment, an increasing number of patients are eligible for hepatic resection at an early stage and hepatic resection has been established as a safe and an effective treatment modality. However, the long-term prognosis of HCC remains unsatisfactory because of a high incidence of tumor recurrence after hepatic resection. Even though intrahepatic recurrence is more common than extrahepatic recurrence, transarterial chemoembolization (TACE), percutaneous ethanol injection and radiofrequency ablation, and hepatic reresection or orthotopic liver transplantation have improved the prognosis of HCC significantly.2 x 2 Lee, PH, Lin, WJ, Tsang, YM et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg. 1995; 222: 670–676 Crossref | PubMed | Scopus (89) | Google Scholar See all References , 3 x 3 Shimada, M, Takenaka, K, Gion, T et al. Prognosis of recurrent hapatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996; 111: 720–726 Abstract | Full Text | Full Text PDF | PubMed | Scopus (235) | Google Scholar See all References , 4 x 4 Farges, O, Regimbeau, JM, and Belghiti, J. Aggressive management of recurrence following surgical resection of hepatocellular carcinoma. Hepatogastroenterology. 1998; 45: 1275–1280 PubMed | Google Scholar See all References , 5 x 5 Poon, RTP, Fan, ST, Lo, CM et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma. Long-term results of treatment and prognostic factors. Ann Surg. 1999; 229: 216–222 Crossref | PubMed | Scopus (457) | Google Scholar See all References , 6 x 6 Bates, MJ, Farkas, E, Taylor, D et al. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation. Ann Thorac Surg. 2008; 85: 412–415 Abstract | Full Text | Full Text PDF | PubMed | Scopus (24) | Google Scholar See all References Unlike in case with intrahepatic metastasis, there is no definitive treatment for HCC with extrahepatic metastasis although some chemotherapeutic agents have been known to be effective in selective patients.7 x 7 Mnedez-Sanchez, N, Vasquez-Fernandez, F, Zamora-Valdes, D et al. Sorafenib, systemic therapy for hepatocellular carcinoma. Ann Hepatol. 2008; 7: 46–51 PubMed | Google Scholar See all References In recent studies, pulmonary metastasectomy has been found to improve long-term survival in highly selective cases.8 x 8 Lam, CM, Lo, CM, Yuen, WK et al. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg. 1998; 85: 1198–2000 Crossref | PubMed | Scopus (102) | Google Scholar See all References , 9 x 9 Tominaru, Y, Sasaki, Y, Yamada, T et al. The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg. 2006; 192: 46–51 Abstract | Full Text | Full Text PDF | PubMed | Scopus (64) | Google Scholar See all References , 10 x 10 Nakagawa, T, Kamiyama, T, Nakanishi, K et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg. 2006; 131: 1248–1254 Abstract | Full Text | Full Text PDF | PubMed | Scopus (34) | Google Scholar See all References However, because only a few cases of pulmonary metastasectomy have been described, its role in the treatment of pulmonary metastasis from HCC is still unclear. Further, the indications and prognostic factors have not yet been standardized. This study aimed to present our experience with pulmonary metastasectomy from HCC and evaluate the prognostic factors.

1 August 2010 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
SCSukki Cho
Sukki Cho
ELEung Bae Lee
Eung Bae Lee
This study aimed to investigate the efficacies and complications associated with the 7F catheter inserted in patients with pneumothorax in the emerge

12 August 2016 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
YSYangki Seok
Yangki Seok
ELEungbae Lee
Eungbae Lee
Background This study analyzed the impact of visceral pleural invasion (VPI) on the disease-free survival (DFS) of patients with partly solid pulmonary adenocarcinoma sized 30 mm or smaller. Method This is a retrospective study of 147 patients with surgically resected pathologic N0 pulmonary adenocarcinoma that had a partly solid appearance on preoperative computed tomography. All patients presented with tumors of size 30 mm or smaller. The DFS rate was estimated using Kaplan–Meier method. A multivariate analysis for prognostic factors was performed using the Cox proportional hazards regression model. Results VPI was found in 36 patients. The 5-year DFS in 111 patients without VPI (97.6%) was significantly higher than that in 36 patients with VPI (63%) (p < 0.0001). Univariate analysis revealed three significant poor prognostic predictors: the presence of VPI, the presence of lymphovascular invasion, and the size of the solid component on computed tomography (>20, ≤30 mm). According to the multivariate analysis, VPI was found to be a significant poor prognostic predictor (hazard ratio for DFS = 7.31, 95% confidence interval = 1.444–37.014, p = 0.016). Conclusion VPI is a significant predictor of poor prognosis for small-sized (≤30 mm) partly solid lung adenocarcinoma. Therefore, upstaging of the T factor from T1 to T2 on the basis of VPI as described by the TNM staging system is mandatory regardless of ground-glass opacity in small lung adenocarcinoma.

1 May 2003 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
PDF file
ELEung Bae Lee
Eung Bae Lee
TPTae I.N Park
Tae I.N Park
SPSun H.A Park
Sun H.A Park
JPJae Yong Park
Jae Yong Park
Lung cancer is a predominant cause of cancer deaths throughout the world [ 1 x 1 Shopland, D.R., Eyre, H.-J., and Pechacek, T.F. Smoking-attributable cancer mortality in 1991 (is lung cancer now the leading cause of death among smokers in the United States?) . J Natl Cancer Inst. 1991; 83: 1142–1148 Crossref | PubMed | Scopus (252) | Google Scholar See all References ] [1] . Recent advances in molecular genetics have revealed that multiple tumor suppressor genes (TSGs) are involved in the genesis or progression of lung cancer [ 2 x 2 Minna, J.D., Sekido, Y., Fong, K., and Gazdar, A.F. Molecular biology of lung cancer. in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.) Cancer: principles and practice of oncology. 5th ed. Lippincott, Philadelphia; 1997: 847–857 Google Scholar See all References , 3 x 3 Chan, D.C., Soriano, A., Kane, M.A., Helfrich, B., and Bunn, P.A. Biology of lung cancer. in: H.H. Hansen (Ed.) Textbook of lung cancer. 1st ed. Martin Dunitz, London; 2000: 27–73 Google Scholar See all References ]. Unlike oncogenes, in which an abnormality in one of the two alleles is sufficient to lead to an abnormal function, TSGs are inactivated by two mutational events. The paradigms of such events are a mutation of one allele and a loss of the other allele [ 4 x 4 Knudson, A.G. Mutation and cancer (statistical study of retinoblastoma) . Proc Natl Acad Sci USA. 1971; 68: 820–823 Crossref | PubMed | Scopus (4608) | Google Scholar See all References , 5 x 5 Jones, P.A. and Laird, P.W. Cancer epigenetics comes of age. Nat Genet. 1999; 21: 163–167 Crossref | PubMed | Scopus (1880) | Google Scholar See all References ]. Thus, loss of heterozygosity (LOH) is a landmark of chromosomal regions that may harbor TSGs [ 6 x 6 Stanbridge, E.J. Human tumor suppressor genes. Annu Rev Genet. 1990; 24: 615–617 Crossref | PubMed | Scopus (219) | Google Scholar See all References , 7 x 7 Weinberg, R.A. Tumor suppressor genes. Science. 1991; 254: 1138–1176 Crossref | PubMed | Scopus (1290) | Google Scholar See all References ]. In non–small cell lung cancer (NSCLC), frequent LOH has been demonstrated on several chromosome arms such as 3p, 5q, 8p, 9p, 11p, 13q, 17p, and 22q [ 8 x 8 Hibi, K., Takahashi, T., Yamakawa, K. et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 1992; 7: 445–449 PubMed | Google Scholar See all References , 9 x 9 Sato, S., Nakamura, Y., and Tsuchiya, E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 1994; 54: 5652–5655 PubMed | Google Scholar See all References , 10 x 10 Wistuba, I.I., Behrens, C., Virmani, A.K. et al. Allelic loss of chromosome 8p21–23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res. 1999; 59: 1973–1979 PubMed | Google Scholar See all References , 11 x 11 Merlo, A., Gabrielson, E., Askin, F., and Sidransky, D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res. 1994; 54: 640–642 PubMed | Google Scholar See all References , 12 x 12 Bepler, G. and Garcia-Blanco, M.A. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small cell lung cancer. Proc Natl Acad Sci USA. 1994; 91: 5513–5517 Crossref | PubMed | Scopus (97) | Google Scholar See all References , 13 x 13 Tamuka, K., Zhang, X., Murakami, Y. et al. Deletion of three distinct regions on chromosome 13q in human non-small-cell lung cancer. Int J Cancer. 1997; 74: 45–49 Crossref | PubMed | Scopus (49) | Google Scholar See all References ]. Studies based on the somatic LOH have led to the discovery of several TSGs such as RB, p53, and FHIT [ 14 x 14 Friend, S.H., Bernards, R., Rogelj, S. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986; 323: 643–646 Crossref | PubMed | Scopus (1954) | Google Scholar See all References , 15 x 15 Reissmann, P.T., Koga, H., Takahashi, R. et al. Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene. 1993; 8: 1913–1919 PubMed | Google Scholar See all References , 16 x 16 Takahashi, T., Nau, M.M., Chiba, I. et al. p53 (A frequent target for genetic abnormalities in lung cancer) . Science. 1989; 246: 491–494 Crossref | PubMed | Scopus (955) | Google Scholar See all References , 17 x 17 Ohta, M., Inoue, H., Cotticelli, M.G. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancer. Cell. 1996; 84: 587–597 Abstract | Full Text | Full Text PDF | PubMed | Scopus (1007) | Google Scholar See all References ].

26 May 2016 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
YSYangki Seok
Yangki Seok
ELEungbae Lee
Eungbae Lee
There are several anatomical variations of the pulmonary vein which can cause serious complications in pulmonary lobectomy. We inadvertently divided the left superior pulmonary vein during thoracoscopic left lower lobectomy in a lung cancer patient. Retrospective review of the preoperative computed tomography showed extra-pericardial common trunk of the left pulmonary venous system. Left superior pulmonary vein was reimplanted into stump of divided common trunk via thoracotomy. Awareness of vascular anomalies will help thoracic surgeons to prevent potential morbidity and mortality from complications.